A combined analysis of 70 prostate cancer patients with genomic data from two major trials assessing the role of MDT in oligometastatic prostate cancer patients showed that patients with high-risk mutations (ATM, BRCA1/2, RB1, or TP53) experienced the greatest benefit in PFS from MDT (HR for high-risk = 0.05; HR for no high-risk = 0.42; p-value for interaction = 0.12) [56]. This evidence concerns the gene RB1 and prostate carcinoma.